AURKA/PLK1/CDC25C轴作为INI1缺陷上皮质肉瘤的新疗法标
Akitomo Inoue1, Hidetatsu Outani1, Yoshinori Imura1
1Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan.
Cancer science
|January 10, 2025
概括
缺少INI1蛋白质的上皮质肉瘤 (EpS) 细胞依赖于AURKA/PLK1/CDC25C途径进行生长. 使用alisertib抑制这一轴显示出对EPS治疗的治疗前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 表皮状肉瘤 (EpS) 是一种具有攻击性的软组织肉瘤,缺乏有效的治疗方法.
- INI1 缺乏是 EpS 的标志,但其功能后果仍然不清楚.
- 极光激酶A (AURKA) /波罗样激酶1 (PLK1) /细胞分裂周期25C (CDC25C) 轴对细胞周期进展至关重要.
研究的目的:
- 调查INI1损失在EPS病变发生中的作用.
- 探索INI1缺陷与AURKA/PLK1/CDC25C轴之间的关联.
- 评估在EPS中准这一轴的治疗潜力.
主要方法:
- 在EPS细胞系中重新引入INI1.
- 通过siRNA介导的AURKA的沉默.
- 用选择性AURKA抑制剂alisertib进行治疗.
- 细胞增殖试验,细胞周期分析,细胞亡试验和异种移植研究.
主要成果:
- 通过降低AURKA/PLK1/CDC25C的调节,INI1的重新引入减少了EPS细胞的增殖和瘤性.
- 通过使用alisertib抑制AURKA沉默或抑制,抑制了EPS细胞生长,并诱导了细胞循环停止和细胞亡.
- 阿利塞尔蒂布在减少异种移植瘤生长方面表现出显著的有效性,这取决于INI1缺乏.
- 具有INI1损失的EPS细胞对AURKA/PLK1/CDC25C轴表现出依赖性.
结论:
- 通过持续激活AURKA/PLK1/CDC25C途径,EPS中的INI1损失驱动瘤生长.
- 针对AURKA/PLK1/CDC25C轴是一个有前途的治疗策略,用于表皮性肉瘤.
- 阿利塞尔蒂布显示出作为针对INI1缺乏的EPS的向治疗的潜力.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Abnormal Proliferation
4.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
The JAK-STAT Signaling Pathway
8.7K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.7K


